Literature DB >> 18417735

Minireview: nuclear receptors and breast cancer.

Suzanne D Conzen1.   

Abstract

Until recently, the study of nuclear receptor (NR) function in breast cancer biology has been largely limited to estrogen and progesterone receptors. The development of reliable gene expression arrays, real-time quantitative RT-PCR, and immunohistochemical techniques for studying NR superfamily members in primary human breast cancers has now revealed the presence and potential importance of several additional NRs in the biology of breast cancer. These include receptors for steroid hormones (including androgens and corticosteroids), fat-soluble vitamins A and D, fatty acids, and xenobiotic lipids derived from diet. It is now clear that after NR activation, both genomic and nongenomic NR pathways can coordinately activate growth factor signaling pathways. Advances in our understanding of both NR functional networks and epithelial cell growth factor signaling pathways have revealed a frequent interplay between NR and epithelial cell growth factor family signaling that is clinically relevant to breast cancer. Understanding how growth factor receptors and their downstream kinases are activated by NRs (and vice-versa) is a central goal for maximizing treatment opportunities in breast cancer. In addition to the estrogen receptor, it is predicted that modulating the activity of other NRs will soon provide novel prevention and treatment approaches for breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417735      PMCID: PMC2582530          DOI: 10.1210/me.2007-0421

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  132 in total

1.  AIB1 enhances estrogen-dependent induction of cyclin D1 expression.

Authors:  M D Planas-Silva; Y Shang; J L Donaher; M Brown; R A Weinberg
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1.

Authors:  C A Mikosz; D R Brickley; M S Sharkey; T W Moran; S D Conzen
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

3.  NCOR1 mRNA is an independent prognostic factor for breast cancer.

Authors:  Zhenhuan Zhang; Hiroko Yamashita; Tatsuya Toyama; Hiroshi Sugiura; Yoshiaki Ando; Keiko Mita; Maho Hamaguchi; Yasuo Hara; Shunzo Kobayashi; Hirotaka Iwase
Journal:  Cancer Lett       Date:  2005-07-12       Impact factor: 8.679

Review 4.  Nuclear receptors and lipid physiology: opening the X-files.

Authors:  A Chawla; J J Repa; R M Evans; D J Mangelsdorf
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

5.  Extranuclear expression of hormone receptors in primary breast cancer.

Authors:  R Kim; M Kaneko; K Arihiro; M Emi; K Tanabe; S Murakami; A Osaki; K Inai
Journal:  Ann Oncol       Date:  2006-06-07       Impact factor: 32.976

6.  Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases.

Authors:  V Boonyaratanakornkit; M P Scott; V Ribon; L Sherman; S M Anderson; J L Maller; W T Miller; D P Edwards
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

7.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

Review 8.  Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer.

Authors:  C J Narvaez; G Zinser; J Welsh
Journal:  Steroids       Date:  2001 Mar-May       Impact factor: 2.668

9.  Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network.

Authors:  Angie L Bookout; Yangsik Jeong; Michael Downes; Ruth T Yu; Ronald M Evans; David J Mangelsdorf
Journal:  Cell       Date:  2006-08-25       Impact factor: 41.582

10.  Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.

Authors:  M Dowsett; J Cuzick; A Howell; I Jackson
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

View more
  62 in total

1.  Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis.

Authors:  Sheila Ganti; Sandra L Taylor; Omran Abu Aboud; Joy Yang; Christopher Evans; Michael V Osier; Danny C Alexander; Kyoungmi Kim; Robert H Weiss
Journal:  Cancer Res       Date:  2012-05-24       Impact factor: 12.701

2.  Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.

Authors:  Tetsuyo Maeda; Yoko Nakanishi; Yukari Hirotani; Fumi Fuchinoue; Katsuhisa Enomoto; Kenichi Sakurai; Sadao Amano; Norimichi Nemoto
Journal:  Med Mol Morphol       Date:  2015-05-26       Impact factor: 2.309

3.  Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs.

Authors:  Luigi Cicatiello; Margherita Mutarelli; Oli M V Grober; Ornella Paris; Lorenzo Ferraro; Maria Ravo; Roberta Tarallo; Shujun Luo; Gary P Schroth; Martin Seifert; Christian Zinser; Maria Luisa Chiusano; Alessandra Traini; Michele De Bortoli; Alessandro Weisz
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

4.  Exploring Binding Mechanisms in Nuclear Hormone Receptors by Monte Carlo and X-ray-derived Motions.

Authors:  Christoph Grebner; Daniel Lecina; Victor Gil; Johan Ulander; Pia Hansson; Anita Dellsen; Christian Tyrchan; Karl Edman; Anders Hogner; Victor Guallar
Journal:  Biophys J       Date:  2017-03-28       Impact factor: 4.033

5.  Induction of the fatty acid 2-hydroxylase (FA2H) gene by Δ(9)-tetrahydrocannabinol in human breast cancer cells.

Authors:  Shuso Takeda; Mari Harada; Shengzhong Su; Shunsuke Okajima; Hiroko Miyoshi; Kazutaka Yoshida; Hajime Nishimura; Yoshiko Okamoto; Toshiaki Amamoto; Kazuhito Watanabe; Curtis J Omiecinski; Hironori Aramaki
Journal:  J Toxicol Sci       Date:  2013       Impact factor: 2.196

6.  Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.

Authors:  A Papi; T Guarnieri; G Storci; D Santini; C Ceccarelli; M Taffurelli; S De Carolis; N Avenia; A Sanguinetti; A Sidoni; M Orlandi; M Bonafé
Journal:  Cell Death Differ       Date:  2012-01-20       Impact factor: 15.828

7.  Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites.

Authors:  Christian Atsriku; David J Britton; Jason M Held; Birgit Schilling; Gary K Scott; Bradford W Gibson; Christopher C Benz; Michael A Baldwin
Journal:  Mol Cell Proteomics       Date:  2008-11-03       Impact factor: 5.911

Review 8.  Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases.

Authors:  Mayur Choudhary; Goldis Malek
Journal:  J Biomol Screen       Date:  2016-07-28

9.  The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study.

Authors:  Adela Castillejo; Trinidad Mata-Balaguer; Carla Guarinos; María-Isabel Castillejo; Ana Martínez-Cantó; Víctor-Manuel Barberá; Paola Montenegro; Enrique Ochoa; Rafael Lázaro; Carmen Guillén-Ponce; Alfredo Carrato; José-Luís Soto
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

10.  HRTBLDb: an informative data resource for hormone receptors target binding loci.

Authors:  Brian A Kennedy; Wenqing Gao; Tim H-M Huang; Victor X Jin
Journal:  Nucleic Acids Res       Date:  2009-09-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.